The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...